196 related articles for article (PubMed ID: 29313669)
1. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
3. Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.
Gentile DR; Rathinaswamy MK; Jenkins ML; Moss SM; Siempelkamp BD; Renslo AR; Burke JE; Shokat KM
Cell Chem Biol; 2017 Dec; 24(12):1455-1466.e14. PubMed ID: 29033317
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity.
Müller MP; Jeganathan S; Heidrich A; Campos J; Goody RS
Sci Rep; 2017 Jun; 7(1):3687. PubMed ID: 28623374
[TBL] [Abstract][Full Text] [Related]
5. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
Goody RS; Müller MP; Rauh D
Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
[TBL] [Abstract][Full Text] [Related]
6. GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site.
Lu S; Banerjee A; Jang H; Zhang J; Gaponenko V; Nussinov R
J Biol Chem; 2015 Nov; 290(48):28887-900. PubMed ID: 26453300
[TBL] [Abstract][Full Text] [Related]
7. High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site.
Chavan TS; Jang H; Khavrutskii L; Abraham SJ; Banerjee A; Freed BC; Johannessen L; Tarasov SG; Gaponenko V; Nussinov R; Tarasova NI
Biophys J; 2015 Dec; 109(12):2602-2613. PubMed ID: 26682817
[TBL] [Abstract][Full Text] [Related]
8. Two Distinct Structures of Membrane-Associated Homodimers of GTP- and GDP-Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement.
Lee KY; Fang Z; Enomoto M; Gasmi-Seabrook G; Zheng L; Koide S; Ikura M; Marshall CB
Angew Chem Int Ed Engl; 2020 Jun; 59(27):11037-11045. PubMed ID: 32227412
[TBL] [Abstract][Full Text] [Related]
9. KRAS
Cagir A; Azmi AS
Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
[No Abstract] [Full Text] [Related]
10. Comparison of ras-p21 bound to GDP and GTP: differences in protein and ligand dynamics.
Mello LV; van Aalten DM; Findlay JB
Protein Eng; 1997 Apr; 10(4):381-7. PubMed ID: 9194162
[TBL] [Abstract][Full Text] [Related]
11. An NMR comparison of the changes produced by different guanosine 5'-triphosphate analogs in wild-type and oncogenic mutant p21ras.
Miller AF; Halkides CJ; Redfield AG
Biochemistry; 1993 Jul; 32(29):7367-76. PubMed ID: 8338834
[TBL] [Abstract][Full Text] [Related]
12. Electrostatic control of GTP and GDP binding in the oncoprotein p21ras.
Muegge I; Schweins T; Langen R; Warshel A
Structure; 1996 Apr; 4(4):475-89. PubMed ID: 8740369
[TBL] [Abstract][Full Text] [Related]
13. Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence.
Vo U; Vajpai N; Flavell L; Bobby R; Breeze AL; Embrey KJ; Golovanov AP
J Biol Chem; 2016 Jan; 291(4):1703-1718. PubMed ID: 26565026
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
15. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
16. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
17. Nucleotide binding and GTP hydrolysis by the 21-kDa product of the c-H-ras gene as monitored by proton-NMR spectroscopy.
Löw A; Sprinzl M; Limmer S
Eur J Biochem; 1993 Apr; 213(2):781-8. PubMed ID: 8386636
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional structure of p21 in the active conformation and analysis of an oncogenic mutant.
Wittinghofer F; Krengel U; John J; Kabsch W; Pai EF
Environ Health Perspect; 1991 Jun; 93():11-5. PubMed ID: 1773783
[TBL] [Abstract][Full Text] [Related]
19. Kinetic and structural analysis of the Mg(2+)-binding site of the guanine nucleotide-binding protein p21H-ras.
John J; Rensland H; Schlichting I; Vetter I; Borasio GD; Goody RS; Wittinghofer A
J Biol Chem; 1993 Jan; 268(2):923-9. PubMed ID: 8419371
[TBL] [Abstract][Full Text] [Related]
20. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.
Lu J; Bera AK; Gondi S; Westover KD
Biochemistry; 2018 Jan; 57(3):324-333. PubMed ID: 29235861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
